A Clinical Risk Score for Thyroid Hormone Therapy After Partial Thyroidectomy
Journal of Surgical Research · 2025
DOI: 10.1016/j.jss.2025.07.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Research, 2025. Verfasst von Elias Mimouni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Thyroidectomy, Thyroxine, Hypothyroidism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
INTRODUCTION: The need for thyroid hormone therapy (levothyroxine [LT4]) after partial thyroidectomy varies with clinical factors, including the preoperative thyroid stimulating hormone (TSH) level and diagnosis. The goal of this study was to develop an easy-to-use clinical risk score to predict the need for LT4 after partial thyroidectomy. METHODS: This is a retrospective cohort study of patients who underwent partial thyroidectomy between 2013 and 2020 at a single institution. The primary outcome was postoperative LT4 therapy. Univariable and multivariable logistic regression evaluated the relationship between covariates and LT4 therapy. Covariates selected by lasso regression as significantly associated with LT4 therapy were incorporated into a weighted risk score. Performance characteristics for the risk score were assessed. RESULTS: Of 425 patients, the median preoperative TSH was 1.4 uIU/mL interquartile range: 0.9-2.0), and 101 patients (23.8%) had a diagnosis of hypothyroidism. In total, 41.9% (n = 178) of patients required LT4 supplement after partial thyroidectomy. On multivariable logistic regression, non-Black race (odds ratio [OR]: 3.40, P < 0.001), preoperative TSH ≥1.59 (OR: 3.51, P < 0.001), and cancer diagnosis (OR: 2.08, P < 0.001) remained significantly associated with LT4 therapy and were incorporated into a clinical risk score. Rates of LT4 use increased with risk score points (0-2: 14%; 3-4: 34%; 5-6: 58%, 7-8: 75%). The model had a negative predictive value of 75% for LT4 therapy. CONCLUSIONS: This simple risk score can be easily derived from data in the health record and can be used to counsel patients about likelihood of needing LT4 after partial thyroidectomy and guide clinical discussions about the extent of surgery in patients with thyroid nodules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Heather.Wachtel@pen…
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Institutes of Health National Cancer Institute
Zitieren
APA
Mimouni, E., Passman, J. E., Alexis, M., Ginzberg, S. P., Fraker, D., Kelz, R., & Wachtel, H. (2025). A Clinical Risk Score for Thyroid Hormone Therapy After Partial Thyroidectomy. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2025.07.015
Vancouver
Mimouni E, Passman JE, Alexis M, Ginzberg SP, Fraker D, Kelz R, et al. A Clinical Risk Score for Thyroid Hormone Therapy After Partial Thyroidectomy. Journal of Surgical Research. 2025. doi:10.1016/j.jss.2025.07.015
BibTeX
@article{Mimouni2025,
author = {Mimouni, Elias and Passman, Jesse E and Alexis, Maya and Ginzberg, Sara P and Fraker, Douglas and Kelz, Rachel and Wachtel, Heather},
title = {A Clinical Risk Score for Thyroid Hormone Therapy After Partial Thyroidectomy},
journal = {Journal of Surgical Research},
year = {2025},
doi = {10.1016/j.jss.2025.07.015}
}
EUVIMED